Altimmune, Inc. Common Stock

ALTNASDAQ • USD
ThemeBiotech - Drug Development›Metabolic & Cardiometabolic
2.71 USD
↘ 0.21 (7.19%)AT CLOSE (11:59 AM EDT)
2.71
↘ 0.01 (0.19%)
POST MARKET (AS OF 07:54 PM EDT)
Post Market
AS OF 07:54 PM EDT
2.71
↘ 0.01 (0.19%)
🔴Market: CLOSED
Open?$2.92
High?$2.92
Low?$2.69
Prev. Close?$2.92
Volume?3.1M
Avg. Volume?3.8M
VWAP?$2.76
Rel. Volume?0.83x
Bid / Ask
Bid?$2.35 × 100
Ask?$3.09 × 100
Spread?$0.74
Midpoint?$2.72
Valuation & Ratios
Market Cap?527.0M
Shares Out?194.5M
Float?104.2M
Float %?92.4%
P/E Ratio?N/A
P/B Ratio?1.86
EPS?-$0.47
Dividend?0.00%
Ex-Dividend?N/A

Shares of Altimmune, Inc. Common Stock (ALT) are trading at $2.71. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics place ALT at a fair price relative to peers.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Themes
Biotech - Drug Development›Metabolic & Cardiometabolic
Employees
57
Market Cap
527.0M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.altimmune.com
Listed
2005-10-06
Address
910 CLOPPER ROAD
GAITHERSBURG, MD 20878
Phone: (240) 654-1450
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
84
Momentum?
50
Short Sent.?
25
Piotroski F-Score?0/9Weak
Altman Z-Score?3.52Safe
Confidence?45%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?36.12%Squeeze Risk
Short Interest?37.6M
Days to Cover?11.0
Free Float104.2M
Avg Daily Volume3.4M
Settlement Date2026-05-15
Financial Health
Current Ratio?29.55Strong
Quick Ratio?29.55Strong
Cash Ratio?8.62Strong
Debt/Equity?0.12Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
78
1.86CHEAP▾
P/S?
Peers
100
S&P
3
14,639.58HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-4.8CHEAP▾
EV/Sales?
Peers
100
S&P
3
12,886.92HIGH▾
Returns & Efficiency
ROE?
S&P
6
-32.2%WEAK▾
ROA?
S&P
3
-27.2%WEAK▾
Cash Flow & Enterprise
FCF?$-71669000
Enterprise Value?$463.9M
Fundamentals ratios updated end of day
MarketsMoversWatchlist